These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 25070319)

  • 1. Bone mineral content in patients with congenital generalized lipodystrophy is unaffected by metreleptin replacement therapy.
    Christensen JD; Lungu AO; Cochran E; Collins MT; Gafni RI; Reynolds JC; Rother KI; Gorden P; Brown RJ
    J Clin Endocrinol Metab; 2014 Aug; 99(8):E1493-500. PubMed ID: 25070319
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term metreleptin treatment increases bone mineral density and content at the lumbar spine of lean hypoleptinemic women.
    Sienkiewicz E; Magkos F; Aronis KN; Brinkoetter M; Chamberland JP; Chou S; Arampatzi KM; Gao C; Koniaris A; Mantzoros CS
    Metabolism; 2011 Sep; 60(9):1211-21. PubMed ID: 21741057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin.
    Diker-Cohen T; Cochran E; Gorden P; Brown RJ
    J Clin Endocrinol Metab; 2015 May; 100(5):1802-10. PubMed ID: 25734254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Leptin Therapy on Survival in Generalized and Partial Lipodystrophy: A Matched Cohort Analysis.
    Cook K; Ali O; Akinci B; Foss de Freitas MC; Montenegro RM; Fernandes VO; Gupta D; Lou KJ; Tuttle E; Oral EA; Brown RJ
    J Clin Endocrinol Metab; 2021 Jul; 106(8):e2953-e2967. PubMed ID: 33822100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.
    Meehan CA; Cochran E; Kassai A; Brown RJ; Gorden P
    Expert Rev Clin Pharmacol; 2016; 9(1):59-68. PubMed ID: 26465174
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metreleptin therapy lowers plasma angiopoietin-like protein 3 in patients with generalized lipodystrophy.
    Muniyappa R; Abel BS; Asthana A; Walter MF; Cochran EK; Remaley AT; Skarulis MC; Gorden P; Brown RJ
    J Clin Lipidol; 2017; 11(2):543-550. PubMed ID: 28502512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metreleptin and generalized lipodystrophy and evolving therapeutic perspectives.
    Tchang BG; Shukla AP; Aronne LJ
    Expert Opin Biol Ther; 2015 Jul; 15(7):1061-75. PubMed ID: 26063386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preadipocyte factor-1 levels are higher in women with hypothalamic amenorrhea and are associated with bone mineral content and bone mineral density through a mechanism independent of leptin.
    Aronis KN; Kilim H; Chamberland JP; Breggia A; Rosen C; Mantzoros CS
    J Clin Endocrinol Metab; 2011 Oct; 96(10):E1634-9. PubMed ID: 21795455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy.
    Moran SA; Patten N; Young JR; Cochran E; Sebring N; Reynolds J; Premkumar A; Depaoli AM; Skarulis MC; Oral EA; Gorden P
    Metabolism; 2004 Apr; 53(4):513-9. PubMed ID: 15045701
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metreleptin replacement treatment improves quality of life and psychological well-being in congenital generalized lipodystrophy.
    Simsir IY; Yurekli BS; Polat I; Saygili F; Akinci B
    Natl Med J India; 2020; 33(5):278-280. PubMed ID: 34213454
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term effectiveness and safety of metreleptin in the treatment of patients with generalized lipodystrophy.
    Brown RJ; Oral EA; Cochran E; Araújo-Vilar D; Savage DB; Long A; Fine G; Salinardi T; Gorden P
    Endocrine; 2018 Jun; 60(3):479-489. PubMed ID: 29644599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of growth hormone therapy and puberty on bone and body composition in children with idiopathic short stature and growth hormone deficiency.
    Högler W; Briody J; Moore B; Lu PW; Cowell CT
    Bone; 2005 Nov; 37(5):642-50. PubMed ID: 16139578
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapeutic indications and metabolic effects of metreleptin in patients with lipodystrophy syndromes: Real-life experience from a national reference network.
    Mosbah H; Vantyghem MC; Nobécourt E; Andreelli F; Archambeaud F; Bismuth E; Briet C; Cartigny M; Chevalier B; Donadille B; Daguenel A; Fichet M; Gautier JF; Janmaat S; Jéru I; Legagneur C; Leguier L; Maitre J; Mongeois E; Poitou C; Renard E; Reznik Y; Spiteri A; Travert F; Vergès B; Zammouri J; Vigouroux C; Vatier C
    Diabetes Obes Metab; 2022 Aug; 24(8):1565-1577. PubMed ID: 35445532
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Metreleptin in Pediatric Patients With Lipodystrophy.
    Brown RJ; Meehan CA; Cochran E; Rother KI; Kleiner DE; Walter M; Gorden P
    J Clin Endocrinol Metab; 2017 May; 102(5):1511-1519. PubMed ID: 28324110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A case of generalized lipodystrophy-associated progeroid syndrome treated by leptin replacement with short and long-term monitoring of the metabolic and endocrine profiles.
    Fukaishi T; Minami I; Masuda S; Miyachi Y; Tsujimoto K; Izumiyama H; Hashimoto K; Yoshida M; Takahashi S; Kashimada K; Morio T; Kosaki K; Maezawa Y; Yokote K; Yoshimoto T; Yamada T
    Endocr J; 2020 Feb; 67(2):211-218. PubMed ID: 31708526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Leptin Attenuates Cardiac Hypertrophy in Patients With Generalized Lipodystrophy.
    Nguyen ML; Sachdev V; Burklow TR; Li W; Startzell M; Auh S; Brown RJ
    J Clin Endocrinol Metab; 2021 Oct; 106(11):e4327-e4339. PubMed ID: 34223895
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metreleptin Treatment in a Boy with Congenital Generalized Lipodystrophy due to Homozygous c.465_468delGACT (p.T156Rfs*8) Mutation in the
    Özalkak Ş; Demiral M; Ünal E; Taş FF; Onay H; Demirbilek H; Özbek MN
    J Clin Res Pediatr Endocrinol; 2023 Aug; 15(3):329-333. PubMed ID: 35735786
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant human leptin treatment in genetic lipodystrophic syndromes: the long-term Spanish experience.
    Araujo-Vilar D; Sánchez-Iglesias S; Guillín-Amarelle C; Castro A; Lage M; Pazos M; Rial JM; Blasco J; Guillén-Navarro E; Domingo-Jiménez R; del Campo MR; González-Méndez B; Casanueva FF
    Endocrine; 2015 May; 49(1):139-47. PubMed ID: 25367549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metreleptin (Myalept): a leptin analog for generalized lipodystrophy.
    Med Lett Drugs Ther; 2015 Jan; 57(1460):13-4. PubMed ID: 25581107
    [No Abstract]   [Full Text] [Related]  

  • 20. Leptin Decreases Energy Expenditure Despite Increased Thyroid Hormone in Patients With Lipodystrophy.
    Grover A; Quaye E; Brychta RJ; Christensen J; Startzell MS; Meehan CA; Valencia A; Marshall B; Chen KY; Brown RJ
    J Clin Endocrinol Metab; 2021 Sep; 106(10):e4163-e4178. PubMed ID: 33890058
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.